Canada markets open in 5 hours 22 minutes
  • S&P/TSX

    20,461.93
    +60.44 (+0.30%)
     
  • S&P 500

    4,448.98
    +53.34 (+1.21%)
     
  • DOW

    34,764.82
    +506.50 (+1.48%)
     
  • CAD/USD

    0.7878
    -0.0024 (-0.31%)
     
  • CRUDE OIL

    73.26
    -0.04 (-0.05%)
     
  • BTC-CAD

    57,107.70
    +669.93 (+1.19%)
     
  • CMC Crypto 200

    1,120.32
    +11.40 (+1.03%)
     
  • GOLD FUTURES

    1,754.90
    +5.10 (+0.29%)
     
  • RUSSELL 2000

    2,259.04
    +40.48 (+1.82%)
     
  • 10-Yr Bond

    1.4100
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,233.50
    -70.00 (-0.46%)
     
  • VOLATILITY

    19.64
    -1.23 (-5.89%)
     
  • FTSE

    7,060.44
    -17.91 (-0.25%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • CAD/EUR

    0.6709
    -0.0018 (-0.27%)
     

Zymergen Investor Alert

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Zymergen To Contact Him Directly To Discuss Their Options

New York, New York--(Newsfile Corp. - August 4, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zymergen Inc. ("Zymergen" or the "Company") (NASDAQ: ZY).

If you suffered losses exceeding $50,000 investing in Zymergen stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/ZY.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.

On April 22, 2021, Zymergen registered and made available through an initial public offering over 16 million shares of common stock at an offering price of $31 per share, raising over $500 million in gross proceeds.

Less than four months later, Zymergen revealed that its only current product is struggling in the market, a major target for future business is not panning out, and that its chief executive officer is stepping down. On this news, the price of Zymergen's common stock plummeted over 75% to trade below $8.50 per share on August 4, 2021.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92123

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting